MRX vs. BGC, SNEX, FRGE, TOP, GSIW, ICE, CME, NDAQ, TW, and LPLA
Should you be buying Medicis Pharmaceutical stock or one of its competitors? The main competitors of Medicis Pharmaceutical include BGC Group (BGC), StoneX Group (SNEX), Forge Global (FRGE), TOP Financial Group (TOP), Garden Stage (GSIW), Intercontinental Exchange (ICE), CME Group (CME), Nasdaq (NDAQ), Tradeweb Markets (TW), and LPL Financial (LPLA). These companies are all part of the "security & commodity brokers, dealers, exchanges & services" industry.
Medicis Pharmaceutical vs.
BGC Group (NASDAQ:BGC) and Medicis Pharmaceutical (NYSE:MRX) are both mid-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
BGC Group currently has a consensus target price of $14.50, suggesting a potential upside of 55.41%. Medicis Pharmaceutical has a consensus target price of $42.67, suggesting a potential downside of 4.94%. Given BGC Group's stronger consensus rating and higher probable upside, research analysts clearly believe BGC Group is more favorable than Medicis Pharmaceutical.
BGC Group pays an annual dividend of $0.08 per share and has a dividend yield of 0.9%. Medicis Pharmaceutical pays an annual dividend of $0.56 per share and has a dividend yield of 1.2%. BGC Group pays out 29.6% of its earnings in the form of a dividend. BGC Group has increased its dividend for 1 consecutive years.
In the previous week, BGC Group had 9 more articles in the media than Medicis Pharmaceutical. MarketBeat recorded 10 mentions for BGC Group and 1 mentions for Medicis Pharmaceutical. BGC Group's average media sentiment score of 0.30 beat Medicis Pharmaceutical's score of 0.00 indicating that BGC Group is being referred to more favorably in the media.
Medicis Pharmaceutical has lower revenue, but higher earnings than BGC Group.
BGC Group has a net margin of 5.59% compared to Medicis Pharmaceutical's net margin of 0.00%. BGC Group's return on equity of 47.55% beat Medicis Pharmaceutical's return on equity.
BGC Group received 162 more outperform votes than Medicis Pharmaceutical when rated by MarketBeat users. However, 67.92% of users gave Medicis Pharmaceutical an outperform vote while only 59.96% of users gave BGC Group an outperform vote.
52.1% of BGC Group shares are owned by institutional investors. 26.3% of BGC Group shares are owned by company insiders. Comparatively, 3.8% of Medicis Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
BGC Group beats Medicis Pharmaceutical on 12 of the 18 factors compared between the two stocks.
Get Medicis Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicis Pharmaceutical Competitors List
Related Companies and Tools
This page (NYSE:MRX) was last updated on 5/24/2025 by MarketBeat.com Staff
